Market Pulse: U.S. futures ripped higher yesterday after gains in AI names and memory chip makers drove enthusiasm into the close.
Key Movers: Alibaba’s renewed AI push and Micron’s solid earnings fuelled the rally, while Lupin’s FDA nod for an HIV treatment pushed its shares into the spotlight.
Macro & Politics: The White House faced pushback over a claim tying autism risk to OTC painkillers, reminding us politics and health science rarely mix cleanly.
What’s Next: Keep an eye on any Fed rate-cut signals and fresh AI announcements from the usual suspects before today’s open.
Unfiltered Market Commentary
Everyone’s overlooking that futures rally on the “US stock futures rise as Nasdaq, S&P 500 rebound on Alibaba’s AI pledge and Micron earnings” (The Times of India) reeks of déjà vu hype without real profit visibility. Investors piled into “Lupin shares gain 2% after USFDA approval for HIV drug” (The Times of India) and ditched Stitch Fix after its earnings beat (“Closing Bell Movers: Stitch Fix slips” – Thefly.com) like it was radioactive.
Meanwhile, lawmakers pivoting on the “A new bill’s bid to bring better sunscreens” (Popular Science) and the White House fumble in “Health Experts Push Back On Trump’s Tylenol And Autism Claims” (Forbes) show how regulatory and political turbulence can tank unrelated sectors in a heartbeat. Combine that with biotech breakthroughs screaming for capital, and you’ve got a recipe for rotation chaos.
Here’s what you do: scale back on deeply hyped AI names and load up on proven drug plays — think UniQure’s 196% leap on Huntington’s results (“Uniqure stock soars 196%” – The Times of India) or hedge with Sequana Medical’s H1 progress (GlobeNewswire). Don’t get blindsided by headlines; pick firms with real catalysts and rerate potential.
📈 Breaking Financial News
Lupin shares gain 2% after USFDA approval for HIV drug
Lupin's shares surged by 2.2% following tentative U.S. FDA approval for its generic HIV treatment, Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets. This positions Lupin to enter a significant U.S. market segment with estimated annual sales of $1…
Closing Bell Movers: Stitch Fix slips 4% despite earnings beat
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
Solana Price Prediction: SOL Targets $500 as Bitcoin Eyes $200,000, While Little Pepe Gears Up for a 45x Blowout
Big institutions are piling into Solana like it’s the last lifeboat—17 treasuries holding 17.1 M SOL, $3.7 B in fresh DeFi inflows and a $12.9 B TVL have traders salivating at a $500 target. Bitcoin’s exchange reserves are evaporating faster than free pizza at a crypto meetup, fueling $200K calls if this liquidity squeeze keeps up. But the real moonshot? Little Pepe’s presale just cleared $25.9 M, building its own L2 to vaporize gas fees and bot scams, and primed for a potential 45× blastoff tha
Press release: Sequana Medical announces H1 2025 results and provides business update
Sequana Medical announces H1 2025 results and provides business update alfapump® US commercialisation underway; Strengthened US reimbursement with…
Why one retail investing platform is betting on physical storefronts for traders
Stock trading platform Moomoo is launching a physical storefront in New York City, looking to tap into retail traders' desire for community support.
Is This the End of Tesla?
The media says Tesla is on the ropes, and the “woke mob” is attacking. But they're missing the big picture. A silent partner is powering Elon Musk's $9 trillion comeback. This is your chance to profit while they're distracted.
🔍 Market Analysis & Insights
SoCalBio Investor & Partnership Conference to Feature Keynotes from SetPoint CEO Murthy Simhambhatla, PhD, and MedTech Industry Deal-Maker Ray Cohen
Keynotes for the 27th SoCalBio Conference will be delivered by Murthy Simhambhatla, PhD (SetPoint Medical) and Raymond W. Cohen (formerly Axonics)…….
Health Experts Push Back On Trump’s Tylenol And Autism Claims
In this week’s edition of InnovationRx, we look at a startup working to fix drug pricing, Pfizer’s obesity bet and more.
Uniqure stock soars 196% after breakthrough Huntington’s disease drug results
Qure stock: UniQure's stock soared after AMT-130 gene therapy demonstrated a statistically significant slowing of Huntington's disease progression in a Phase I/II study. The high-dose treatment arm showed a 75% reduction in disease progression at 36 months, w…
Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRA
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) and certain officers. The class action, filed in the United States District Court …
US stock futures rise as Nasdaq, S&P 500 rebound on Alibaba’s AI pledge and Micron earnings; Fed rate cut debate in focus
US stock futures moved up as investors looked at AI growth and company earnings. Alibaba raised its AI spending plan and Micron gave strong results, bringing more hope to the market. Traders are also waiting for the inflation report and housing data this week…
The Real Reason 218,000 Acres Just Vanished
The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake. Find out why this could be the most lucrative “underground” energy story in America.
💰 Investment Opportunities
A new bill’s bid to bring better sunscreens
The SAFE Sunscreen Standards Act seeks to revamp the FDA’s review process. Could it usher in more effective sunscreens? The post A new bill’s bid to bring better sunscreens appeared first on Popular Science.
Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-25-012 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit applications to participate in a consortium of Research Centers focused on designing, optimizing, evaluating,…
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
Basel, 24 September 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) presents new data for OCREVUS® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st Congress of the European Committee for Treatment and Research …
The White House Kicks Tylenol Into Crisis Mode Again. Will Its PR Playbook Work This Time?
Robert Andrews would forever remember when his phone rang on Friday, September 30, 1982. He was assistant director for PR at Johnson & Johnson, whose pain reliever, Tylenol, was the […]
Nyxoah Provides an Update on Expanded Middle East Presence
Nyxoah Provides an Update on Expanded Middle East Presence New Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region……
I'm a Futurist: Here are 4 stocks better than Nvidia
Nvidia's own customers could soon become fierce competitors, dethroning the AI Chip King. But there's a critical component that AI data centers need just as badly as chips. The demand is so massive that a single data center uses enough of it to stretch around the earth eight times. While the media hypes up AI chips, the smart money has found the next big thing. Discover Futurist Eric Fry's “Nvidia-killer” stock ideas.